The STIMULUS Clinical Trial Program: Evaluating Combination Therapy with MBG453 in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) or Acute Myeloid Leukemia

被引：0

作者：

Zeidan, Amer ^{[1
,2
]}

Esteve, Jordi ^{[3
]}

Kim, Hee-Je ^{[4
]}

Miyazaki, Yasushi ^{[5
]}

Platzbecker, Uwe ^{[6
]}

Schuh, Andre ^{[7
]}

Westermann, Joerg ^{[8
]}

Malek, Kamel ^{[9
]}

Scott, Jeffrey ^{[10
]}

Niolat, Julie ^{[11
]}

Peyrard, Severine ^{[11
]}

Kiertsman, Flavia ^{[10
]}

Stegert, Mario ^{[9
]}

Fenaux, Pierre ^{[12
]}

机构：

[1] Yale Univ, New Haven, CT USA

[2] Yale Canc Ctr, New Haven, CT USA

[3] Hosp Clin Barcelona, Barcelona, Spain

[4] Catholic Univ Korea, Catholic Hematol Hosp, Coll Med, Seoul, South Korea

[5] Nagasaki Univ, Nagasaki, Japan

[6] Univ Hosp Leipzig, Leipzig, Germany

[7] Princess Margaret Canc Ctr, Toronto, ON, Canada

[8] Charite Univ Med Ctr Berlin, Campus Virchow Clin, Berlin, Germany

[9] Novartis Pharma AG, Basel, Switzerland

[10] Novartis Pharmaceut, E Hanover, NJ USA

[11] Novartis Pharma SAS, Rueil Malmaison, France

[12] Hop St Louis, Paris, France

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷

关键词：

acute myeloid leukemia; clinical trial; immunotherapy; myelodysplasia; AML;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

AML-187

引用

页码：S188 / S188

页数：1

共 50 条

[41] The Prognostic Utility of the Current Risk Models in Predicting Outcomes of Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agents (HMA)
Zeidan, Amer M.
Sekeres, Mikkael A.
Garcia-Manero, Guillermo
Barnard, John
Al Ali, Najla H.
Zimmerman, Cassie
Roboz, Gail J.
Steensma, David P.
DeZern, Amy E.
Jabbour, Elias
Kantarjian, Hagop
Zell, Katrina
Wang, Quiqing
Gore, Steven D.
Nazha, Aziz
Maciejewski, Jaroslaw P.
List, Alan F.
Komrokji, Rami S.
BLOOD, 2014, 124 (21)
[42] Impact Of Magrolimab in Combination With Azacitidine on Red Blood Cells (RBCs) in Patients With Higher-Risk Myelodysplastic Syndromes (HR MDS)
Chen, James
Johnson, Lisa
McKenna, Kelly
Choi, Timothy
Duan, Jiaqi
Feng, Dongdong
Tsai, Jonathan
Garcia-Martin, Natalia
Sompalli, Kavitha
Maute, Roy
Vyas, Paresh
Majeti, Ravindra
Takimoto, Chris
Liu, Jie
Ramsingh, Giridharan
Chao, Mark
Volkmer, Jens-Peter
Weissman, Irving
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S317 - S318
[43] Clinical outcomes associated with azacitidine (AZA) monotherapy for treatment-naive, higher-risk myelodysplastic syndrome (HR-MDS): A systematic literature review and meta-analysis.
Hasegawa, Ken
Wei, Andrew H.
Garcia-Manero, Guillermo
Daver, Naval Guastad
Rajakumaraswamy, Nishanthan
Iqbal, Shahed
Chan, Rebecca J.
Hu, Hao
Tse, Preston
Yan, Jiajun
Zoratti, Michael J.
Xie, Feng
Sallman, David Andrew
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[44] NOVEL PREDICTIVE INDICATORS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC NEOPLASMS (HR-MDS) TREATED WITH 5-AZACYTIDINE: CUMULATIVE DATA FROM THE HELLENIC MDS STUDY GROUP
Kotsianidis, I.
Hatzimichael, E.
Pappa, V.
Galanopoulos, A.
Kourakli, A.
Diamantopoulos, P.
Papageorgiou, S.
Liapis, K.
Papadopoulos, V.
Papoutselis, M.
Bouchla, A.
Georgoulis, V.
Vassilakopoulos, T.
Solomou, E.
Dimou, M.
Vassilopoulos, G.
Vardi, A.
Papaioannou, M.
Pontikoglou, C.
Anagnostopoulos, A.
Panayiotidis, P.
Kontopidou, F.
Harchalakis, N.
Adamopoulos, N.
Ximeri, M.
Zikos, P.
Megalakaki, A.
Repousis, P.
Kotsopoulou, M.
Dryllis, G.
Tsoukanas, D.
Kyrtsonis, M. -C.
Poulakidas, E.
Bouronikou, E.
Delimpasis, S.
Mparmparousi, D.
Papadaki, H.
Vyniou, N. A.
Symeonidis, A.
LEUKEMIA RESEARCH, 2023, 128
[45] Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HRMDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study
Brunner, Andrew M.
Esteve, Jordi
Porkka, Kimmo
Knapper, Steve
Traer, Elie
Scholl, Sebasttian
Garcia-Manero, Guillermo
Vey, Norbert
Wermke, Martin
Janssen, Jeroen
Narayan, Rupa
Loo, Sun
Kontro, Mika
Ottmann, Oliver
Naidu, Purushotham
Pelletier, Marc
Han, May
Lewandowski, Andrew
Zhang, Na
Mohammed, Anisha
Rinne, Mikael L.
Borate, Uma
Wei, Andrew H.
Tovar, Natalia
BLOOD, 2021, 138
[46] Comparison of Transfusion Requirements in High Risk Myelodysplastic Syndromes (HR-MDS) and Secondary Acute Myeloid Leukemia (sAML) Treated with Azacitidine or Intensive Chemotherapy
Alonso Nogues, E.
Garcia Caro, M.
Xicoy, B.
Morgades, M.
Linio, R.
San Miguel, L.
Gallardo, A.
Prieto, M.
Grifols, J.
Ribera, J.
TRANSFUSION, 2013, 53 : 189A - 189A
[47] An Assessment of the RIFLE Criteria for Acute Kidney Injury (AKI) and Mortality in Patients (Pts) with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS).
Mattiuzzi, Gloria
Lahoti, Amit
Salahudeen, Abdulla
Ravandi, Farhad
Cortes, Jorge
Vu, Khanh
Kantarjian, Hagop
BLOOD, 2009, 114 (22) : 419 - 420
[48] Lenalidomide and Risk of Acute Myeloid Leukemia (AML) Transformation Among Myelodysplastic Syndrome (MDS) Patients
Rollison, Dana E.
Shain, Kenneth H.
Lee, Ji-Hyun
Hampras, Shalaka S.
Fulp, William
Fisher, Kate
Al Ali, Najla H.
Padron, Eric
Lancet, Jeffrey
Xu, Qiang
Knight, Robert D.
List, Alan F.
Dalton, William
Komrokji, Rami
BLOOD, 2014, 124 (21)
[49] Lemzoparlimab, a differentiated anti-CD47 monoclonal antibody, in combination with azacitidine (AZA) in patients with newly diagnosed higher risk myelodysplastic syndrome (HR-MDS): Initial clinical results
Xiao, Z.
Chang, C.
Li, Q.
Yan, X.
Qin, T.
Tong, H.
Dai, M.
He, Y.
Weng, J.
Li, J.
Gao, S.
Fu, R.
Wei, X.
Ma, X.
Zhang, Y.
Huang, W.
Wang, Q.
Gu, L.
Meng, Y.
Zhu, A.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S827 - S827
[50] Molecular, Epigenetic, and Immune Landscape of TP53-mutated (TP53-M) Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)
Bewersdorf, Jan Philipp
Hasle, Vanessa
Shallis, Rory Michael
Thompson, Ethan G.
de Menezes, Daniel Lopes
Rose, Shelonitda
Boss, Isaac W.
Halene, Stephanie
Haferlach, Torsten
Fox, Brian
Zeidan, Amer M.
BLOOD, 2022, 140 : 6247 - 6249

← 1 2 3 4 5 →